XTX Topco’s Niagen Bioscience NAGE Stock Holding History

XTX Topco’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63.6K	Sell	19,924 -9,991	-33%	-$40.5K	﹤0.01%	3653
2026 Q1	$132K	Sell	29,915 -15,050	-33%	-$81.3K	﹤0.01%	3007
2025 Q4	$286K	Sell	44,965 -9,457	-17%	-$65.8K	0.01%	2122
2025 Q3	$508K	Buy	54,422 +4,732	+10%	+$47.8K	0.03%	1061
2025 Q2	$716K	Buy	+49,690	New	+$491K	0.03%	866
2025 Q1	–	Sell	-22,697	Closed	-$120K	–	3271
2024 Q4	$120K	Buy	+22,697	New	+$124K	0.01%	1726
2024 Q1	–	Sell	-17,265	Closed	-$24.7K	–	2422
2023 Q4	$24.7K	Buy	17,265 +3,644	+27%	+$5.08K	0.01%	1340
2023 Q3	$19.9K	Buy	+13,621	New	+$21.3K	﹤0.01%	1376
2022 Q2	–	Sell	-30,998	Closed	-$76K	–	1155
2022 Q1	$76K	Buy	+30,998	New	+$84.7K	0.03%	548
2021 Q3	–	Sell	-12,528	Closed	-$124K	–	1120
2021 Q2	$124K	Buy	+12,528	New	+$109K	0.04%	632

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

XTX Topco's NAGE Position: Q2 2026 in Review

XTX Topco reduced its Niagen Bioscience (NAGE) stake by 33% in Q2 2026, selling an estimated $40.5K and leaving 19,924 shares worth $63.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3653.

XTX Topco first reported a position in NAGE in Q2 2021 and has held it in 10 quarters since. The position peaked at $716K in Q2 2025. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

XTX Topco held 19,924 shares of Niagen Bioscience worth $63.6K as of Q2 2026.
XTX Topco sold 9,991 Niagen Bioscience shares in Q2 2026, an estimated $40.5K.
Niagen Bioscience made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3653 holding.
XTX Topco first reported a position in Niagen Bioscience in Q2 2021 and has held it in 10 quarters since.
XTX Topco's Niagen Bioscience position peaked at $716K in Q2 2025.
139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.